Which is worse? A company removes a cancer medicine from the PBS and commits to continuing to supply it to patients for free. Or, an advisory committee that disregards patient and clinician input, rejects a submission, and supports delaying treatment until it is literally too late and the patient is close to death.
These outcomes are mostly about the choices Australia is making
June 17, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australian company partners to take innovative therapy to Asia
June 17, 2026 - - Latest News -
Novartis names interim leader for Australia and NZ after Country President departs
June 17, 2026 - - Latest News -
These outcomes are mostly about the choices Australia is making
June 17, 2026 - - Latest News -
AstraZeneca confirms pricing the issue, and acts to create a patient access program
June 16, 2026 - - Latest News -
When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution
June 16, 2026 - - Latest News -
Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder
June 15, 2026 - - Australian Biotech -
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - - Australian Biotech

